Peter Thiel is totally flawed about Alzheimer’s

The New York Occasions ran a lengthy interview this morning between columnist Ross Douthat and enterprise capitalist and PayPal founder Peter Thiel. There is a cause it was printed within the opinion part.

Thiel, a Trump booster whose allies — together with Vice President JD Vance — now litter the White Home, was given free reign to debate a wide range of subjects throughout over an hour of softball questions. Is Greta Thunberg the literal antichrist? Are the three predominant ideological colleges in Europe environmentalism, “Islamic Shariah legislation” and “Chinese language Communist totalitarian takeover”? Is AI “woke” and able to following Elon Musk to Mars? Peter appears to suppose so! Maybe the “simply asking questions” college of journalism may add “hey, what the fuck are you speaking about” to its repertoire.

Admittedly, many of those assertions fall squarely into the realm of issues that exist inside Thiel’s thoughts palace slightly than verifiable details, with a minimum of one notable exception. Comparatively early of their chat, Peter tells Ross the next [emphasis ours]:

It is a fairly daring declare! It is also fully unfaithful.

“There was no therapy 40 or 50 years in the past for Alzheimer’s illness,” Sterling Johnson, a professor of Geriatrics and Gerontology on the College of Wisconsin, Madison, advised Engadget. “What we have been capable of do within the final 20 years has been really fairly extraordinary. We have developed markers that assist us establish when this illness begins, utilizing the utilizing amyloid markers and tau biomarkers, we all know that the illness really begins 20 years earlier than the signs do, and that may be a crucial factor to know if we’re going to stop this illness.”

In the intervening time, Alzheimer’s stays incurable. However the absence of a miracle treatment doesn’t negate the accomplishments to this point in detection and prevention. “The primary therapies had been these window dressing therapies. It is like treating the signs such as you would deal with a chilly […] The primary technology of amyloid remedy was that sort of strategy the place it simply addressed the signs by amping up the neurons and rising the neurotransmitters out there to the to the mind cells.” Johnson, whose group runs one of many largest and longest studies on folks in danger for growing Alzheimer’s illness, added, “Now we have now alternatives to really modify the illness biology by way of the amyloid pathway, but in addition we’re targeted on the opposite proteinopathy — which is tau — and there is medical trials underway.”

Thiel, a widely known advocate for developments in radical life extension (together with a reported curiosity in injecting himself with the blood of younger folks) sees the state of scientific analysis on this space as sluggish and danger averse. However the groundbreaking work is going on at this second. Professor Johnson pointed to a monoclonal antibody known as gantenerumab. In an early take a look at of 73 individuals with inherited mutations that may trigger them to overproduce amyloid within the mind, it lower the variety of individuals who developed Alzheimer’s signs virtually in half. “The massive part three prevention trials [of gantenerumab] are taking place proper now.”

For somebody who fashions himself as a heterodox thinker, Thiel definitely appears to have came upon a remarkably comparable speaking level to present Trump administration FDA head Robert F Kennedy Jr. “Alzheimer’s is a really, superb instance of how [National Institute of Health] has gone off the rails over the previous 20 years in the past with analysis on amyloid plaques” Kennedy said at a Division of Well being budgetary listening to final month. He claimed the NIH was “reducing off every other speculation” attributable to “corruption.”

Unsurprisingly, the Alzheimer’s Affiliation has known as this “demonstrably false.”

“In actuality, over the latest 10 years out there (2014-2023), less than 14% of recent Nationwide Institutes of Well being (NIH) Alzheimer’s initiatives targeted on amyloid beta because the therapeutic goal,” the group wrote, “As of September 2024, the National Institute on Aging was investing in 495 pharmacological and non-pharmacological trials. To state that Alzheimer’s analysis is targeted on amyloid to the exclusion of different targets is clearly flawed.”

If I, personally, needed extra strong medical analysis and an opportunity an everlasting life (I do not), greasing the wheels of an administration broadly gutting funding for science could be a wierd technique to make that occur. However that is the type of incoherence we have come to anticipate from tech oligarchs: they are saying what advantages them, even when it is nonsense on its face, even when a second’s reflection reveals it to be patently false. What’s embarrassing is the paper of file giving them free reign to do it.